Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378531 · ClinicalTrials.gov registry record · Phase 2
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
A Phase 2 study of Hyperargininemia and Arginase I Deficiency, sponsored by Aeglea Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 7
- Study locations
NCT03378531 is a Phase 2 study of Hyperargininemia and Arginase I Deficiency that has completed, run by Aeglea Biotherapeutics. The registered enrollment target is 14 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT03378531, a Phase 2 study of Hyperargininemia and Arginase I Deficiency, has completed, sponsored by Aeglea Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to investigate the long-term safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who complete Study CAEB1102-101A.
Conditions Studied
Interventions
- DRUG AEB1102
Study Locations (7)
Other
- Centro Hospitalar S. Joao - Porto
- Great Ormond Street Hospital - London
California
- Stanford University School of Medicine - Stanford
Florida
- University of Florida - Gainesville
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- UTSW - Dallas
Ontario
- The Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03378531
The ClinicalTrials.gov registry entry for NCT03378531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aeglea Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hyperargininemia appearing as the primary indexed condition, and to 1 intervention - of which AEB1102 is the first listed.
NCT03378531 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03378531 about?
NCT03378531 is a clinical study titled "A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency". The purpose of this study is to investigate the long-term safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who complete Study CAEB1102-101A.
What is the current status of trial NCT03378531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2017-12-07. Estimated completion is 2022-12-15.
What conditions does trial NCT03378531 study?
This clinical trial studies the following conditions: Hyperargininemia, Arginase I Deficiency.
What interventions are being tested in trial NCT03378531?
The interventions under investigation include: AEB1102 (DRUG).
Who is sponsoring clinical trial NCT03378531?
This trial is sponsored by Aeglea Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03378531 being conducted?
This trial has 7 study locations across California, Florida, New York, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperargininemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.